Heteromultivalent particle compositions

US9833518B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9833518-B2
Application numberUS-201514827785-A
CountryUS
Kind codeB2
Filing dateAug 17, 2015
Priority dateApr 13, 2012
Publication dateDec 5, 2017
Grant dateDec 5, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.

First claim

Opening claim text (preview).

Having described the invention, we claim: 1. A method of delivering a therapeutic and/or imaging agent to activated platelets in a subject, the method comprising administering to the subject a composition, the composition comprising a heteromultivalent nanoparticle or microparticle construct comprising a therapeutic agent and/or imaging agent, the nanoparticle or microparticle construct having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle construct, a first activated platelet targeting moiety comprising a GPIIb-IIIa-binding peptide and a second activated platelet targeting moiety comprising a p-selectin binding peptide, wherein the nanoparticle or microparticle construct remains attached to activated platelets in the subject under a hemodynamic shear environment. 2. The method of claim 1 , the nanoparticle or microparticle construct comprising a liposome. 3. The method of claim 1 , the GPIIb-IIIa-binding peptide comprising a RGD peptide and the p-selectin binding peptide comprising the sequence of SEQ ID NO: 1. 4. The method of claim 3 , the RGD peptide having the sequence of SEQ ID NO: 3. 5. The method of claim 1 , wherein the first and second activated platelet targeting moieties are conjugated to the nanoparticle or microparticle construct surface with PEG linkers. 6. The method of claim 1 , wherein the targeting moieties are spatially or topographically arranged on the nanoparticle or microparticle construct surface such that the GPIIb-IIIa-binding peptide and the p-selectin binding peptide do not spatially mask each other and the nanoparticle or microparticle construct is able to bind to an activated platelet with exposed activated platelet receptors and enhance retention of the nanoparticle or microparticle construct onto activated platelets under hemodynamic flow. 7. The method of claim 6 , wherein the ratio of GPIIb-IIIa-binding peptide to p-selectin binding peptide provided on the nanoparticle or microparticle construct surface is about 80:20 to about 20:80. 8. The method of claim 6 , wherein the GPIIb-IIIa-binding peptide and p-selectin binding peptide provided on the nanoparticle or microparticle construct surface have a total mol % of about 5 to about 20 with respect to total lipid content. 9. The method of claim 1 , wherein the therapeutic agent is a thrombolytic agent and the subject is afflicted with an occlusive vascular disease selected from the group consisting of stroke, myocardial infarction, peripheral arterial diseases and deep vein thrombosis. 10. The method of claim 1 , the nanoparticle or microparticle construct further comprising a plurality of Golden Nanorods (GNRs) conjugated to the surface, the GNRs allowing photothermal destabilization of the nanoparticle or microparticle construct and release of the therapeutic and/or imaging agent in response to near-infrared (NIR) light.

Assignees

Inventors

Classifications

  • Human Necessities · mapped topic

  • Methine dyes, e.g. cyanine dyes · CPC title

  • Urokinase; Tissue plasminogen activator · CPC title

  • Fluorescein, used in vivo · CPC title

  • Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9833518B2 cover?
A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety.
Who is the assignee on this patent?
Univ Case Western Reserve
What technology area does this patent fall under?
Primary CPC classification A61K47/48815. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).